The covalent complex of LCN2 and MMP-9 has been associated with enhancing invasion and metastasis in breast cancer [12]–[14], poorer clinical outcome and improved migration in gastric cancer, [15], [16], and increased depth of tumour invasion in esophageal cancer [11]. Here, LCN2 is linked to breast carcinoma.